167 related articles for article (PubMed ID: 38235148)
1. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
Liao JB; Swensen RE; Ovenell KJ; Hitchcock-Bernhardt KM; Reichow JL; Apodaca MC; D'Amico L; Childs JS; Higgins DM; Buening BJ; Goff BA; Disis ML
Gynecol Oncol; 2017 Mar; 144(3):480-485. PubMed ID: 28089377
[TBL] [Abstract][Full Text] [Related]
3. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.
Kong Y; Zhao X; Xu M; Pan J; Ma Y; Zou L; Peng Q; Zhang J; Su C; Xu Z; Zhou W; Peng Y; Yang J; Zhou C; Li Y; Guo Q; Chen G; Wu H; Xing P; Zhang L
Front Immunol; 2022; 13():952066. PubMed ID: 35874780
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
Baur M; Schernhammer E; Gneist M; Sevelda P; Speiser P; Hudec M; Dittrich Ch
Br J Cancer; 2005 Mar; 92(6):1019-25. PubMed ID: 15756278
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
Liu Z; Wang F; Zhang Y; Lu J; Yang Y
Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
8. A tolerability and safety analysis of adding granulocyte-macrophage colony-stimulating factor to local radiotherapy in a case series of seven patients with thoracic cancer.
Wang BC; Li PC; Kuang BH; Zhang ZJ; Xiao BY; Lin GH; Liu Q
Ann Palliat Med; 2021 Apr; 10(4):4193-4200. PubMed ID: 33832300
[TBL] [Abstract][Full Text] [Related]
9. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
Niu J; Kundranda MN; Markman M; Farley J
Eur J Gynaecol Oncol; 2017; 38(1):40-44. PubMed ID: 29767862
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
[TBL] [Abstract][Full Text] [Related]
11. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer.
Kinney RE; Nair S; Kim CH; Thomas MB; DelaTorre M
Oncologist; 2023 Jun; 28(6):e478-e486. PubMed ID: 37027520
[TBL] [Abstract][Full Text] [Related]
13. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
Xu H; Hong Z; Xu M; Kong Y; Ma Y; Shan C; Xing P; Zhang L
Front Immunol; 2022; 13():926740. PubMed ID: 35874658
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
Horikawa N; Abiko K; Matsumura N; Baba T; Hamanishi J; Yamaguchi K; Murakami R; Taki M; Ukita M; Hosoe Y; Koshiyama M; Konishi I; Mandai M
Br J Cancer; 2020 Mar; 122(6):778-788. PubMed ID: 31932754
[TBL] [Abstract][Full Text] [Related]
15. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
17. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
20. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.
Wallenfriedman MA; Conrad JA; DelaBarre L; Graupman PC; Lee G; Garwood M; Gregerson DS; Jean WC; Hall WA; Low WC
J Neurosurg; 1999 Jun; 90(6):1064-71. PubMed ID: 10350253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
